Cargando…
Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy
A substantial obstacle to the success of adoptive T cell-based cancer immunotherapy is the sub-optimal affinity of T-cell receptors (TCRs) for most tumor antigens. Genetically engineered TCRs that have enhanced affinity for specific tumor peptide-MHC complexes may overcome this barrier. However, thi...
Autores principales: | Sanderson, Joseph P, Crowley, Darragh J, Wiedermann, Guy E, Quinn, Laura L, Crossland, Katherine L, Tunbridge, Helen M, Cornforth, Terri V, Barnes, Christopher S, Ahmed, Tina, Howe, Karen, Saini, Manoj, Abbott, Rachel J, Anderson, Victoria E, Tavano, Barbara, Maroto, Miguel, Gerry, Andrew B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959444/ https://www.ncbi.nlm.nih.gov/pubmed/32002290 http://dx.doi.org/10.1080/2162402X.2019.1682381 |
Ejemplares similares
-
Preclinical safety testing of an affinity-optimised MAGE-A10 T cell receptor for adoptive T cell therapy
por: Gerry, Andrew, et al.
Publicado: (2015) -
Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate
por: Border, Ellen C., et al.
Publicado: (2018) -
Tuning T‐Cell Receptor Affinity to Optimize Clinical Risk‐Benefit When Targeting Alpha‐Fetoprotein–Positive Liver Cancer
por: Docta, Roslin Y., et al.
Publicado: (2019) -
Pathogenicity of the MAGE family
por: Li, Sanyan, et al.
Publicado: (2021) -
In vivo enhancement of the MAGE-specific cellular immune response by a recombinant MAGE1-MAGE3-TBHSP70 tumor vaccine
por: Junwei, Wang, et al.
Publicado: (2016)